Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore
Tyra Biosciences shares were last quoted at $33.02 before Friday’s regular Nasdaq session, keeping the clinical-stage biotech below its 52-week high as investors weighed a fresh rare-cancer awareness push against a year still driven by trial data. The stock’s 52-week range was $8.75 to $40.65, with market value near $2 billion. Friday is not a U.S. stock-market holiday. Nasdaq’s calendar lists Memorial Day, Monday, May 25, as closed, leaving TYRA set for a normal regular session unless company-specific news or broader biotech flows shift the tape.